Abstract
To analyze whether Oxaliplatin (OXA) is effective in advanced gastric cancer. Clinical trials of OXA-based chemotherapy (treatment group) versus DDP-based chemotherapy (control group) in advanced gastric cancer which published in 6 years were retrieved from China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP information database and PubMed of U.S. National Library of Medicine and NIH. Review Manager 4.2 was used for meta-analysis and main outcome measure included objective response rate, survival and toxicities. There were 2121 patients (1062 cases in treatment group and 1059 cases in control group) from 16 controlled clinical trials were enrolled. Response rate increased (46.3% vs 40.6%, OR = 1.28, P = 0.006) and 1-year survival rate increased (44.6% vs 39.3%, OR = 1.25, P = 0.04) in treatment group than that of control group. Peripheral neurotoxicity was more frequently observed in treatment group (70.6% vs 21.9%, OR = 10.76, P < 0.01) while anemia and nausea/vomiting were reversed (58.0% vs 70.1%, 61.4% vs 75.6% respectively, both P < 0.05). Oxaliplatin-based chemotherapy is well-tolerated and more effective than cisplatin in advanced gastric cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
